These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22124474)

  • 21. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
    J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
    Guirgis HM
    J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
    Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
    Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
    Asukai Y; Valladares A; Camps C; Wood E; Taipale K; Arellano J; Cassinello A; Sacristán JA; Dilla T
    BMC Cancer; 2010 Jan; 10():26. PubMed ID: 20113499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
    Hong J; Kyung SY; Lee SP; Park JW; Jung SH; Lee JI; Park SH; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
    Korean J Intern Med; 2010 Sep; 25(3):294-300. PubMed ID: 20830227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
    Krawczyk P; Kowalski DM; Wojas-Krawczyk K; Mlak R; Jaśkiewicz P; Kucharczyk T; Winiarczyk K; Krzakowski M; Milanowski J
    Chemotherapy; 2012; 58(1):60-9. PubMed ID: 22338650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
    de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
    J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
    Yoshimura N; Okishio K; Mitsuoka S; Kimura T; Kawaguchi T; Kobayashi M; Hirashima T; Daga H; Takeda K; Hirata K; Kudoh S
    J Thorac Oncol; 2013 Jan; 8(1):96-101. PubMed ID: 23207920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.